In: Oncogene, 2021, vol. 40, no. 7, p. 1205–1216
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully i mplemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate...
|
In: Langenbeck's Archives of Surgery, 2015, vol. 400, no. 6, p. 675-682
|
Mémoire de bachelor : Haute école de santé Genève, 2020.
L'objectif de cette revue de littérature, est d'identifier les interventions infirmières permettant de soutenir les hommes atteints du cancer de la prostate faisant face à de l'incertitude et de décrire leurs vécus face à celle-ci. Les bases de données Pubmed et Cinhal on été consultées entre le 3 décembre 2019 et le 14 février 2020. Parmi les huit études retenues, les devis...
|
Mémoire de bachelor : Haute école de gestion de Genève, 2020 ; TDIBM 101.
The Fourth Industrial Revolution represents both challenges and opportunities for companies, but more importantly, it raises questions about what decisions should be made and what their implications would be. There are two dimensions to this new era of economic disruption that can be seen as opposed or complementary: job automation and soft skill development for humans. Often, discussing...
|
In: Cancers, 2020, vol. 12, no. 1, p. 23 p
In this study, we extracted prostate cell-specific gene sets (metagenes) to define the epithelial differentiation status of prostate cancers and, using a deconvolution-based strategy, interrogated thousands of primary and metastatic tumors in public gene profiling datasets. We identified a subgroup of primary prostate tumors with low luminal epithelial enrichment (LumElow). LumElow tumors were...
|
In: Nature communications, 2016, vol. 7, p. 13719
Activation of NOTCH signalling is associated with advanced prostate cancer and treatment resistance in prostate cancer patients. However, the mechanism that drives NOTCH activation in prostate cancer remains still elusive. Moreover, preclinical evidence of the therapeutic efficacy of NOTCH inhibitors in prostate cancer is lacking. Here, we provide evidence that PTEN loss in prostate tumours ...
|
In: European Journal of Nuclear Medicine and Molecular Imaging, 2014, vol. 41, no. 9, p. 1744-1755
|
In: European Journal of Clinical Pharmacology, 2014, vol. 70, no. 8, p. 983-990
|
In: Cancer Causes & Control, 2014, vol. 25, no. 11, p. 1523-1529
|
In: Supportive Care in Cancer, 2014, vol. 22, no. 9, p. 2425-2434
|